Catalyst Funds Management’s Kinnate Biopharma Inc. Common Stock KNTE Stock Holding History

Catalyst Funds Management’s Portfolio KNTE Stock Details KNTE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q2	–	Sell	-1,570	Closed	-$4.18K	–	1704
2024 Q1	$4.18K	Buy	+1,570	New	+$3.89K	﹤0.01%	993

Catalyst Funds Management's KNTE Position: Q2 2024 in Review

Catalyst Funds Management sold out of Kinnate Biopharma Inc. Common Stock (KNTE) in Q2 2024, closing a stake of 1,570 shares — an estimated $4.18K sold.

Catalyst Funds Management first reported a position in KNTE in Q1 2024 and held it in 1 quarter. The position peaked at $4.18K in Q1 2024. 0 funds tracked by Wall St. Rank hold KNTE as of Q2 2024.

Catalyst Funds Management reported no remaining Kinnate Biopharma Inc. Common Stock position as of Q2 2024 after selling out during the quarter.
Catalyst Funds Management sold 1,570 Kinnate Biopharma Inc. Common Stock shares in Q2 2024, an estimated $4.18K.
Catalyst Funds Management first reported a position in Kinnate Biopharma Inc. Common Stock in Q1 2024 and held it in 1 quarter.
Catalyst Funds Management's Kinnate Biopharma Inc. Common Stock position peaked at $4.18K in Q1 2024.
0 funds tracked by Wall St. Rank held Kinnate Biopharma Inc. Common Stock as of Q2 2024.

Based on Catalyst Funds Management's 13F filing for Q2 2024, filed 18 Dec 2024.